Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches

J Cell Physiol. 2019 Jun;234(6):8636-8646. doi: 10.1002/jcp.27850. Epub 2018 Dec 4.

Abstract

Cancer therapy using oncolytic viruses is an emerging area, in which viruses are engineered to selectively propagate in tumor tissues without affecting healthy cells. Because of the advantages that adenoviruses (Ads) have over other viruses, they are more considered. To achieve tumor selectivity, two main modifications on Ads genome have been applied: small deletions and insertion of tissue- or tumor-specific promoters. Despite oncolytic adenoviruses ability in tumor cell lysis and immune responses stimulation, to further increase their antitumor effects, genomic modifications have been carried out including insertion of checkpoint inhibitors and antigenic or immunostimulatory molecules into the adenovirus genome and combination with dendritic cells and chemotherapeutic agents. This study reviews oncolytic adenoviruses structures, their antitumor efficacy in combination with other therapeutic strategies, and finally challenges around this treatment approach.

Keywords: adenovirus; dendritic cells; immune responses; oncolytic viruses; tumor.

Publication types

  • Review

MeSH terms

  • Adenoviridae / genetics
  • Adenoviridae / growth & development
  • Adenoviridae / immunology
  • Adenoviridae / pathogenicity*
  • Animals
  • Antineoplastic Agents, Immunological / therapeutic use
  • Chemotherapy, Adjuvant
  • Dendritic Cells / immunology
  • Dendritic Cells / transplantation
  • Genetic Therapy
  • Humans
  • Immunotherapy, Adoptive
  • Neoplasms / immunology
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Neoplasms / virology
  • Oncolytic Virotherapy* / adverse effects
  • Oncolytic Viruses / genetics
  • Oncolytic Viruses / growth & development
  • Oncolytic Viruses / immunology
  • Oncolytic Viruses / pathogenicity*
  • Virus Replication

Substances

  • Antineoplastic Agents, Immunological